Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)

Last updated: May 7, 2024
Sponsor: Scripps Whittier Diabetes Institute
Overall Status: Active - Recruiting

Phase

2/3

Condition

Diabetes Mellitus, Type 2

Diabetes Prevention

Diabetes And Hypertension

Treatment

Usual Care - Blinded Continuous Glucose Monitoring Management

Dexcom G6 Continous Glucose Monitoring Management

Clinical Study ID

NCT05307237
R01DK124427
R01DK124427
  • Ages > 18
  • All Genders

Study Summary

Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an underserved and understudied, yet high-risk population. A digital dashboard will facilitate real-time, remote monitoring of a large volume of patients simultaneously; automatically identify and prioritize patients for intervention; and will detect any and all potentially dangerous hypoglycemic episodes in a hospital environment. The study will focus on clinical metrics of glucose control and infection that are in-line with patient priorities and US hospital quality initiatives.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Documented previous or current Type 2 Diabetes (T2D) diagnosis as defined by eitherdiagnosis in the chart or an HbA1c > or = to 6.5% in the last 90 days
  • Either on subcutaneous (SQ) insulin orders, or greater than two serum or Point of Care (POC) glucose > or = 200 mg/dL in most recent 24 hours of admission

Exclusion

Exclusion Criteria:

  • Anticipated length of stay < 24 hours;
  • Current or anticipated ICU placement;
  • Does not speak English or Spanish;
  • Known allergy to adhesives;
  • Current participation in any medication or device research study;
  • Pregnant;
  • Any other condition that Multiple Principal Investigator (MPI) Philis-Tsimikas or theattending physician deems contraindicated

Study Design

Total Participants: 554
Treatment Group(s): 2
Primary Treatment: Usual Care - Blinded Continuous Glucose Monitoring Management
Phase: 2/3
Study Start date:
April 19, 2022
Estimated Completion Date:
November 30, 2025

Study Description

There is strong evidence that poor glycemic control in the hospital is common. Given the known consequences of uncontrolled blood sugars during a hospitalization (e.g., infection, serious neurological and cardiac complications, mortality, longer lengths of stay, readmissions, higher healthcare costs), health systems devote significant resources to developing protocols for improving glucometrics. Despite the widespread use and demonstrated effectiveness of continuous glucose monitoring (CGM) for ambulatory glucose management, CGMs is not routinely used in US hospitals. Therefore, the long-term goal to develop Cloud-Based Real-Time Glucose Evaluation and Management System (Cyber GEMS) is to provide an effective, real-time solution to augment existing processes, to provide a valuable test of real-world effectiveness, while capitalizing on standardized algorithms to facilitate sustainability and scalability to other systems and at-risk populations. The intervention will enable hospital care teams to take immediate steps based on the wireless transmission of glucose data from the Dexcom G6 device, sent to a digital dashboard, where integration with existing real-world hospital processes can provide immediate prioritization to prevent or correct impending hypoglycemia and severe hyperglycemic events. This study is a randomized controlled trial, defined as a Phase II/III definitive clinical trial that in turn establishes efficacy and effectiveness of this intervention. Aim 1 will establish the effectiveness of Cyber GEMS versus Usual Care (UC) in increasing the % time patients are in-range and decreasing % time in hypoglycemia and severe hyperglycemia during hospitalization. Aim 2 will evaluate the effectiveness of Cyber GEMS versus UC in decreasing hospital-acquired infection risk. A digital dashboard will facilitate real-time, wireless transmission of glucose data of a large volume of patients simultaneously; automatically identify and prioritize patients for intervention; and detect potentially dangerous hypoglycemic episodes - all at a reduced burden than current methods of stratification and review. The uninterrupted coverage, and efficient and remote diabetes specialist oversight in Cyber GEMS is a scalable, novel, team-based approach to maximize the use of continuously streaming CGM data for optimal glucose management.

Connect with a study center

  • Scripps Mercy Hospital

    Chula Vista, California 91910
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.